{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:12:05Z","timestamp":1779297125119,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00277-019-03648-4","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:02:47Z","timestamp":1556910167000},"page":"1713-1720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-036X","authenticated-orcid":false,"given":"Alberto","family":"Mussetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Pellegrinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Cieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Garzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Dominoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Montefusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"3648_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle RA et al (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121\u20131127","journal-title":"Leukemia"},{"key":"3648_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1634\/theoncologist.2015-0303","volume":"21","author":"J Caers","year":"2016","unstructured":"Caers J, Fern\u00e1ndez de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, W\u00e4sch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M (2016) The changing landscape of smoldering multiple myeloma: a European perspective. Oncologist 21:333\u2013342","journal-title":"Oncologist"},{"key":"3648_CR3","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125:3049\u20133058","journal-title":"Blood"},{"key":"3648_CR4","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473","journal-title":"Leukemia"},{"key":"3648_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035981","volume":"7","author":"S Feyler","year":"2012","unstructured":"Feyler S, Scott GB, Parrish C, Jarmin S, Evans P, Short M, McKinley K, Selby PJ, Cook G (2012) Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 7:e35981","journal-title":"PLoS One"},{"key":"3648_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","volume":"29","author":"A Ray","year":"2015","unstructured":"Ray A, Das DS, Song Y, Richardson P, Munshi NC, Chauhan D, Anderson KC (2015) Targeting PD1\u2013PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells. Leukemia 29:1441\u20131444","journal-title":"Leukemia"},{"key":"3648_CR7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","volume":"126","author":"MV Dhodapkar","year":"2015","unstructured":"Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B (2015) Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 126:2475\u20132478","journal-title":"Blood"},{"key":"3648_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","volume":"27","author":"H Tamura","year":"2013","unstructured":"Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K (2013) Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27:464\u2013472","journal-title":"Leukemia"},{"key":"3648_CR9","doi-asserted-by":"crossref","first-page":"41228","DOI":"10.18632\/oncotarget.5682","volume":"6","author":"L Wang","year":"2015","unstructured":"Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, Xia ZJ, Lu Y (2015) Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget 6:41228\u201341236","journal-title":"Oncotarget"},{"key":"3648_CR10","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G Gorgun","year":"2015","unstructured":"Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC (2015) Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 21:4607\u20134618","journal-title":"Clin Cancer Res"},{"key":"3648_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/CJI.0b013e31821ca6ce","volume":"34","author":"J Rosenblatt","year":"2011","unstructured":"Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D, Avigan D (2011) PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell\/myeloma fusion vaccine. J Immunother 34:409\u2013418","journal-title":"J Immunother"},{"key":"3648_CR12","first-page":"3089","volume":"130","author":"E Manasanch","year":"2017","unstructured":"Manasanch E et al (2017) Pilot study of pembrolizumab for immunoprevention in smoldering multiple myeloma. Blood 130:3089","journal-title":"Blood"},{"key":"3648_CR13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMp1803602","volume":"379","author":"NJ Gormley","year":"2018","unstructured":"Gormley NJ, Pazdur R (2018) Immunotherapy combinations in multiple myeloma \u2014 known unknowns. N Engl J Med 379:1791\u20131795","journal-title":"N Engl J Med"},{"issue":"2","key":"3648_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-014-0043-z","volume":"3","author":"W Jing","year":"2015","unstructured":"Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD (2015) Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. J Immunother Cancer 3(2):2","journal-title":"J Immunother Cancer"},{"key":"3648_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt SA, Young JW (2016) T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res 4:61\u201371","journal-title":"Cancer Immunol Res"},{"key":"3648_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/sj.onc.1210691","volume":"27","author":"C Scavelli","year":"2008","unstructured":"Scavelli C, Nico B, Cirulli T, Ria R, di Pietro G, Mangieri D, Bacigalupo A, Mangialardi G, Coluccia AML, Caravita T, Molica S, Ribatti D, Dammacco F, Vacca A (2008) Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 27:663\u2013674","journal-title":"Oncogene"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03648-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03648-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T06:53:25Z","timestamp":1607583205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03648-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["3648"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03648-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"assertion":[{"value":"15 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional IRB and all procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}